ArticleInternational journal of clinical and experimental medicine2015
Endogenous FOXP3 inhibits cell proliferation, migration and invasion in glioma cells.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 12 citations in OpenAlex.
- FOXP3 expression in esophageal squamous cell carcinoma : Implications for cetuximab sensitivity and therapeutic strategies.Wiener klinische Wochenschrift · 2024Article
- Identification of FOXP3American journal of physiology. Cell physiology · 2024Article
- Deciphering immune microenvironment and cell evasion mechanisms in human gliomas.Frontiers in oncology · 2023Review
- Gut Microbiome Alterations Affect Glioma Development and Foxp3 Expression in Tumor Microenvironment in Mice.Frontiers in oncology · 2022Article
- CBioMed research international · 2019Article
- The effect of foxp3-overexpressing Treg cells on non-small cell lung cancer cells.Molecular medicine reports · 2018Article
- Epigenetic Variability of CD4+CD25+ Tregs Contributes to the Pathogenesis of Autoimmune Diseases.Clinical reviews in allergy & immunology · 2017Review
- Silencing of Foxp3 delays the growth of murine melanomas and modifies the tumor immunosuppressive environment.OncoTargets and therapy · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The transcription factor forkhead box P3 (FOXP3) has been demonstrated to play important roles in the development and function of regulatory T cells (Tregs). In addition, studies had recently demonstrated that FOXP3 also expressed in some tumor cells. However, the exact role and molecular mechanism of FOXP3 function in glioma's cells are still unclear. This study aims to elucidate the functions of FOXP3 in glioma's cells. Expression of FOXP3 in glioma cell U87 and LN229 was up-regulated and down-regulated by pCMV6-FOXP3-GFP and pRFP-C-RS shFOXP3 respectively. Then, CCK-8 assay, flow cytometry, migration and invasion assay, and western blot were used to detect cell proliferation, cell cycle, cell migration and invasion and related protein expression. All detection methods demonstrated that over-expression of FOXP3 in glioma cell U87 and LN229 inhibited cell proliferation, reduced cell migration, decreased cell invasion compared with control. Moreover, up-regulation of FOXP3 increased the protein levels of pro-apoptotic molecules caspases-3 and caspases-7, resulting in the promotion of cell apoptosis. Conversely down-regulation of the FOXP3 promoted cell growth and inhibited cell apoptosis and reduced the expression of caspases-3 and caspases-7. Our findings suggest that FOXP3 maybe act as a suppressor in glioma cells proliferation, migration and invasion and endogenous FOXP3 transfusion could be a novel approach for inhibiting glioma progression.
Indexed as
Identifiers
25932107PMC4402754W395846479What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.